-
CVS Caremark's Q2 growth prompted by Walgreens-ESI stalemate
WOONSOCKET, R.I. — CVS Caremark’s solid second-quarter performance and outlook has prompted the company to raise yet narrow its guidance for the year. CVS Caremark now expects to deliver adjusted earnings per share of $3.32 to $3.38 for the full year 2012, up from its previous guidance of $3.23 to $3.33.
-
CVS Caremark discusses growth at annual stockholders meeting
Woonsocket, R.I. -- CVS Caremark held its annual meeting of stockholders at its headquarters on Thursday, and the tone attendees heard was a positive one.
According to president and CEO Larry Merlo, the company is well-positioned for growth in an evolving healthcare market.
Merlo made note in the meeting of Walgreens’ battle with Express Scripts, which has created opportunity for CVS to pick up significant prescription business.